Stockreport

MiNK Reports Fourth Quarter and Year-End 2023 Results

MiNK Therapeutics, Inc.  (INKT) 
PDF Launched and enrolling Phase 2 trial of allo-iNKTs with botensilimab/balstilimab and chemotherapy in second-line gastroesophageal cancers Announced collaboration with [Read more]